M

Maat Pharma SA
PAR:MAAT

Watchlist Manager
Maat Pharma SA
PAR:MAAT
Watchlist
Price: 7.82 EUR 2.09% Market Closed
Market Cap: 108.6m EUR
Have any thoughts about
Maat Pharma SA?
Write Note

Maat Pharma SA
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Maat Pharma SA
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
M
Maat Pharma SA
PAR:MAAT
Cash from Financing Activities
€8.1m
CAGR 3-Years
-27%
CAGR 5-Years
80%
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Cash from Financing Activities
€72.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genfit SA
PAR:GNFT
Cash from Financing Activities
-€7.6m
CAGR 3-Years
44%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Inventiva SA
PAR:IVA
Cash from Financing Activities
€53.8m
CAGR 3-Years
-15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Cash from Financing Activities
-€23.5m
CAGR 3-Years
1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
OSE Immunotherapeutics SA
PAR:OSE
Cash from Financing Activities
€8m
CAGR 3-Years
-27%
CAGR 5-Years
104%
CAGR 10-Years
N/A
No Stocks Found

Maat Pharma SA
Glance View

Market Cap
108.8m EUR
Industry
Biotechnology

Maat Pharma SA operates as a clinical-stage microbiome therapeutics company. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 43 full-time employees. The company went IPO on 2021-11-08. The firm specializes in the microbiome therapy that is aimed to treatment of Gut Microbiota alteration (Dysbiosis) using patient-specific biotherapeutics in patients with serious medical conditions. Its MaaT Microbiome Restoration Therapy (MMRB) discovery and analysis platform supports the evaluation of drug candidates, the determination of new disease targets and the identification of biomarkers for microbiome-related conditions.

MAAT Intrinsic Value
7.32 EUR
Overvaluation 6%
Intrinsic Value
Price
M

See Also

What is Maat Pharma SA's Cash from Financing Activities?
Cash from Financing Activities
8.1m EUR

Based on the financial report for Dec 31, 2023, Maat Pharma SA's Cash from Financing Activities amounts to 8.1m EUR.

What is Maat Pharma SA's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
80%

Over the last year, the Cash from Financing Activities growth was 52%. The average annual Cash from Financing Activities growth rates for Maat Pharma SA have been -27% over the past three years , 80% over the past five years .

Back to Top